Q-omics provides the consensus-scored GTSE1 profile across patient tissues and cancer cell-line models. GTSE1 expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, GTSE1 is differentially expressed in 17, with the highest sampling consensus in HNSC. Additionally, GTSE1 RNA expression shows 25,481 significant protein co-abundance associations, with the highest sampling consensus in LUAD. Together, these results highlight ACC, HNSC, and LUAD as cancer lineages where GTSE1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for GTSE1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes GTSE1 survival associations across molecular data types. GTSE1 RNA expression shows survival associations in the most cancer types (26), followed by mutation status (6) and mass-spec protein abundance (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible GTSE1 RNA expression–survival associations across cancer types. High GTSE1 expression shows unfavorable associations in ACC, KIRP, MESO, UVM, LIHC and KIRC. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for GTSE1 RNA expression.
This table summarizes GTSE1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 17, while mass-spec protein shows differences in 5. The strongest signals are observed in HNSC for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for GTSE1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. GTSE1 shows higher tumor expression in HNSC, BLCA, LUAD, KIRP, COAD and KIRC. The HNSC box plot shows higher GTSE1 RNA expression in tumor versus normal tissue (log2 FC = +2.053, t-test p < 0.001).
This table shows molecular features associated with GTSE1 in patient tissues and cancer cell lines. In patient samples, GTSE1 shows the broadest associations at the RNA and protein expression levels, with LUAD recurring as the lineage with the largest associated feature set. In cancer cell lines, GTSE1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_SCLC, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and CNS.
